1. The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, FcγRI and FcγRIII binding.
- Author
-
Morgan, A., Jones, N. D., Nesbitt, A. M., Chaplin, L., Bodmer, M. W., and Emtage, J. S.
- Subjects
- *
AMINO acids , *IMMUNOGLOBULIN G , *GLUTAMIC acid , *EXCITATORY amino acids , *LYSINE , *IMMUNOGLOBULINS - Abstract
We have found that amino acid residues necessary for Clq and FcγR binding of human IgGl are located in the N-terminal region of the CH2 domain, residues 231--238, using a matched set of engineered antibodies based on the anti-HLA-DR antibody L243. Changing the leucine 235 in the CH2 region of IgG3 and IgG4 to glutamic acid was already known to abolish FcγRl binding. We have confirmed this for IgG1 and also found a concomitant abolition of human complement lysis with retention of FcγRIII-mediated function. Changing the glycine at 237 to alanine of IgG1 also abolished FcγRl binding and reduced human complement lysis and FcγRIII-mediated function. Exchanging the whole region 233-236 with the sequence found in human IgG2, abolished FcγRI binding and human complement lysis and reduced FcγRIII-mediated function of IgG1. In contrast, a change in the previously described C1q-binding motif, from lysine at 320 to alanine, had no effect on IgG1-mediated complement lysis. [ABSTRACT FROM AUTHOR]
- Published
- 1995